# Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

> **NCT02568553** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Recurrent Burkitt Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Grade 3a Follicular Lymphoma
- Recurrent Grade 3b Follicular Lymphoma
- Recurrent Gray-Zone Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Mediastinal Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Burkitt Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Follicular Lymphoma
- Refractory Grade 1 Follicular Lymphoma
- Refractory Grade 2 Follicular Lymphoma
- Refractory Grade 3 Follicular Lymphoma
- Refractory Grade 3a Follicular Lymphoma
- Refractory Gray-Zone Lymphoma
- Refractory Mantle Cell Lymphoma
- Refractory Marginal Zone Lymphoma
- Refractory Mediastinal Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Small Lymphocytic Lymphoma

## Interventions

- **BIOLOGICAL:** Blinatumomab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT02568553
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-15
- **Primary completion:** 2025-11-24
- **Final completion:** 2025-11-24
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02568553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02568553, "Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02568553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*